STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Travere Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Guggenheim's 2nd Annual Healthcare Innovation Conference
Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET

Stifel 2025 Healthcare Conference
Wednesday, November 12, 2025

TD Cowen Immunology & Inflammation Summit
Presenting on Thursday, November 13, 2025, at 4:00 p.m. ET

Jefferies Global Healthcare Conference
Presenting on Tuesday, November 18, 2025, at 3:00 p.m. GMT (10:00 a.m. ET)

8th Annual Evercore Healthcare Conference
Presenting on Tuesday, December 2, 2025, at 10:50 a.m. ET

Piper Sandler 37th Annual Healthcare Conference
Wednesday, December 3, 2025

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Investors:

888-969-7879

IR@travere.com

Media:

888-969-7879

mediarelations@travere.com

Source: Travere Therapeutics, Inc.

Travere Therapeutics Inc

NASDAQ:TVTX

TVTX Rankings

TVTX Latest News

TVTX Latest SEC Filings

TVTX Stock Data

3.09B
82.15M
0.75%
117.25%
13.55%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO